Citadel Advisors’s Endocyte, Inc. Common Stock ECYT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2018
Q4 | – | Sell |
-1,361,949
| Closed | -$24.2M | – | 5220 |
|
|
2018
Q3 | $24.2M | Sell |
1,361,949
-639,446
| -32% | -$11.4M | 0.01% | 676 |
|
|
2018
Q2 | $27.6M | Buy |
2,001,395
+1,540,258
| +334% | +$21.3M | 0.01% | 586 |
|
|
2018
Q1 | $4.19M | Buy |
461,137
+110,618
| +32% | +$1.01M | ﹤0.01% | 1387 |
|
|
2017
Q4 | $1.5M | Buy |
350,519
+288,924
| +469% | +$1.24M | ﹤0.01% | 2101 |
|
|
2017
Q3 | $87K | Buy |
+61,595
| New | +$87K | ﹤0.01% | 3361 |
|
|
2017
Q1 | – | Sell |
-15,886
| Closed | -$41K | – | 4432 |
|
|
2016
Q4 | $41K | Sell |
15,886
-23,199
| -59% | -$59.9K | ﹤0.01% | 3340 |
|
|
2016
Q3 | $121K | Buy |
39,085
+14,367
| +58% | +$44.5K | ﹤0.01% | 3165 |
|
|
2016
Q2 | $79K | Sell |
24,718
-26,009
| -51% | -$83.1K | ﹤0.01% | 2998 |
|
|
2016
Q1 | $158K | Sell |
50,727
-39,888
| -44% | -$124K | ﹤0.01% | 2774 |
|
|
2015
Q4 | $363K | Buy |
90,615
+35,582
| +65% | +$143K | ﹤0.01% | 2611 |
|
|
2015
Q3 | $252K | Buy |
55,033
+23,734
| +76% | +$109K | ﹤0.01% | 3045 |
|
|
2015
Q2 | $162K | Buy |
31,299
+13,666
| +78% | +$70.7K | ﹤0.01% | 3112 |
|
|
2015
Q1 | $110K | Sell |
17,633
-75,506
| -81% | -$471K | ﹤0.01% | 3241 |
|
|
2014
Q4 | $586K | Sell |
93,139
-219,477
| -70% | -$1.38M | ﹤0.01% | 2459 |
|
|
2014
Q3 | $1.9M | Buy |
312,616
+233,592
| +296% | +$1.42M | ﹤0.01% | 1607 |
|
|
2014
Q2 | $521K | Buy |
79,024
+70,296
| +805% | +$463K | ﹤0.01% | 2246 |
|
|
2014
Q1 | $208K | Sell |
8,728
-27,720
| -76% | -$661K | ﹤0.01% | 2822 |
|
|
2013
Q4 | $390K | Buy |
+36,448
| New | +$390K | ﹤0.01% | 2163 |
|